
    
      The primary objective of this study is to evaluate the efficacy of ALO-01 compared with
      placebo for the treatment of chronic moderate to severe pain (focusing on osteoarthritis of
      the hip or knee) as measured by mean change in diary Brief Pain Inventory (BPI) score of
      average pain (daily scores of average pain averaged over 7 days) from randomization to 12
      weeks following randomization.
    
  